JPMorgan Chase & Co. set a GBX 7,900 ($103.23) target price on AstraZeneca (LON:AZN) in a research note published on Monday, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the stock. Citigroup reaffirmed a buy rating and issued a GBX 7,000 ($91.47) target price on shares of AstraZeneca in a research report on Monday, May 13th. Credit Suisse Group set a GBX 7,300 ($95.39) price target on AstraZeneca and gave the company a buy rating in a report on Friday, July 26th. Liberum Capital restated a hold rating and issued a GBX 6,400 ($83.63) price target on shares of AstraZeneca in a research note on Wednesday, August 28th. Bryan, Garnier & Co reaffirmed a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Finally, Jefferies Financial Group reiterated a neutral rating on shares of AstraZeneca in a research report on Thursday, August 29th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of GBX 6,956.25 ($90.90).
Shares of AstraZeneca stock opened at GBX 6,917 ($90.38) on Monday. AstraZeneca has a twelve month low of GBX 5,312 ($69.41) and a twelve month high of GBX 7,583 ($99.09). The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The company’s 50 day moving average is GBX 7,124.24 and its 200 day moving average is GBX 6,384.29. The company has a market cap of $90.74 billion and a price-to-earnings ratio of 40.40.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.